Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2017 Jan 21;17(1):38.
doi: 10.1186/s12872-016-0464-3.

Effect of Erythropoietin in patients with acute myocardial infarction: five-year results of the REVIVAL-3 trial

Birgit Steppich  1 , Philip Groha  2 , Tareq Ibrahim  3 , Heribert Schunkert  3 , Karl-Ludwig Laugwitz  3 , Martin Hadamitzky  2 , Adnan Kastrati  2 , Ilka Ott  2 ; Regeneration of Vital Myocardium in ST-Segment Elevation Myocardial Infarction by Erythropoietin (REVIVAL-3) Study Investigators
Affiliations
Randomized Controlled Trial

Effect of Erythropoietin in patients with acute myocardial infarction: five-year results of the REVIVAL-3 trial

Birgit Steppich et al. BMC Cardiovasc Disord. .

Abstract

Background: Erythropoietin (EPO) has been suggested to promote cardiac repair after MI. However, the randomized, double-blind, placebo controlled REVIVAL-3 trial showed that short term high dose EPO in timely reperfused myocardium does not improve left ventricular ejection fraction after 6 months. Moreover, the study raised safety concerns due to a trend towards a higher incidence of adverse clinical events as well as a increase in neointima formation after treatment with EPO. The present study therefore aimed to assess the 5-year clinical outcomes.

Methods: After successful reperfusion 138 patients with STEMI were randomly assigned to receive epoetin beta (3.33×104 U, n = 68) or placebo (n = 70) immediately, 24 and 48 h after percutaneous coronary intervention. The primary outcome of the present study- the combined incidence of MACE 5 years after randomization - occurred in 25% of the patients assigned to epoetin beta and 17% of the patients assigned to placebo (RR 1.5; 95% CI 0.8-3.5; p = 0.26). Target lesion revascularization was required in 15 patients (22.1%) treated with epoetin-ß and 9 patients (12.9%) treated with placebo (p = 0.15). Analysis of patients in the upper and lower quartile of baseline hemoglobin as an indirect estimate of endogenous erythropoietin levels revealed no significant impact of endogenous erythropoietin on efficiency of exogen administered epoetin-ß in terms of death and MACE.

Conclusion: These long-term follow-up data show that epoetin beta does not improve clinical outcomes of patients with acute myocardial infarction.

Trial registration: URL www.clinicaltrials.gov ; Unique identifier NCT00390832; trial registration date October 19th 2006.

Keywords: Acute myocardial infarction; Erythropoietin; REVIVAL-3 trial.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Kaplan-Meier-Curves showing the cumulative event rates according to Epoetin beta therapy or Placebo. A Analysis of survival. B Analysis of survival free of recurrent myocardial infarction (MI). C Analysis of survival free of recurrent MI and stroke. D Analysis of survival free of MACE (recurrent MI, stroke and reintervention)
See this image and copyright information in PMC

References

    1. Campo G, Guastaroba P, Marzocchi A, Santarelli A, Varani E, Vignali L, Sangiorgio P, Tondi S, Serenelli C, De Palma R, Saia F. Impact of COPD on long-term outcome after ST-segment elevation myocardial infarction receiving primary percutaneous coronary intervention. Chest. 2013;144(3):750–757. doi: 10.1378/chest.12-2313. - DOI - PubMed
    1. Campo G, Saia F, Guastaroba P, Marchesini J, Varani E, Manari A, Ottani F, Tondi S, De Palma R, Marzocchi A. Prognostic impact of hospital readmissions after primary percutaneous coronary intervention. Arch Intern Med. 2011;171(21):1948–1949. doi: 10.1001/archinternmed.2011.536. - DOI - PubMed
    1. Campo G, Saia F, Percoco G, Manari A, Santarelli A, Vignali L, Varani E, Benassi A, Sangiorgio P, Tarantino F, Magnavacchi P, De Palma R, Guastaroba P, Marzocchi A. Long-term outcome after drug eluting stenting in patients with ST-segment elevation myocardial infarction: data from the REAL registry. Int J Cardiol. 2010;140(2):154–160. doi: 10.1016/j.ijcard.2008.11.021. - DOI - PubMed
    1. Dominguez-Rodriguez A, Abreu-Gonzalez P, Reiter RJ. Cardioprotection and pharmacological therapies in acute myocardial infarction: Challenges in the current era. World J Cardiol. 2014;6(3):100–106. doi: 10.4330/wjc.v6.i3.100. - DOI - PMC - PubMed
    1. Sanchis-Gomar F, Garcia-Gimenez JL, Pareja-Galeano H, Romagnoli M, Perez-Quilis C, Lippi G. Erythropoietin and the heart: physiological effects and the therapeutic perspective. Int J Cardiol. 2014;171(2):16–125. doi: 10.1016/j.ijcard.2013.12.011. - DOI - PubMed

Publication types

MeSH terms

Associated data